Abstract:Objective To analyze the effect and safety of Levofloxacin in the treatment of multidrug-resistant pulmonary tuberculosis.Methods Eighty patients withmultidrug-resistant pulmonary tuberculosiswho were treated in our hospital from January 2018 to January 2019 were selected as the research objects,and they were divided into the control group(n=40)and the observation group(n=40)by the random listmethod.Patients in the control group received conventional drug treatment,and patients in the observation group received Levofloxacin treatment on the basis of the control group.The therapeutic effect,levels of inflammatory factors(tumor necrosis factor-α [TNF-α],interleukin-6[IL-6],interleukin-1 [IL-1])before and after treatment and the total incidence rate of adverse reactions were observed in the two groups.Results The total effective rate of treatment in the observation group was 97.50%,which was higher than that in the control group accounting for 82.50%,and the difference was statistically significant(P<0.05).The levels of TNF-α,IL-6 and IL-1 after treatment in the two groups were lower than those before treatment,and the differences were statistically significant(P<0.05).The levels of TNF-α,IL-6 and IL-1 after treatment in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).During the drug treatment period,the total incidence rate of adverse reactions in the observation group was 15.00%,compared with 12.50%in the control group,and the difference was not statistically significant(P>0.05).Conclusion Levofloxacin in the treatment of patients withmultidrug-resistant pulmonary tuberculosis can significantly reduce the level of inflammatory factors and improve the therapeutic effect.At the same time,patients have fewer adverse reactions and have higher safety,which is worthy of being promoted and applied.
吴成波. 左氧氟沙星治疗耐多药肺结核的效果与安全性[J]. 中国当代医药, 2020, 27(9): 44-46.
WU Cheng-bo. Effect and safety of Levofloxacin in the treatment of multidrug-resistant pulmonary tuberculosis. 中国当代医药, 2020, 27(9): 44-46.